State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With Deep Brain Stimulation (DBS)

Parkinson's Disease Clinical Trial

Official title:

State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With DBS

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02709148
• Other study ID #: NEURO-2016-24512
• Status: Completed
• Phase: Phase 1
• Start date: July 20, 2017
• Est. completion date: July 31, 2020

Study information

• Verified date: January 2021
• Source: University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to use an investigational device to record brain activity for 12-24 months following surgical implantation of deep brain stimulation (DBS) systems. The goal of the study is better understanding of brain activity in Parkinson's disease and how they relate to DBS and pharmacological management, not to bring new devices to market.

Description:

Experimental: chronic brain recording This is a one-arm, single-center study of the neurophysiology of human movement disorders with two goals: 1) Assess the feasibility of chronic brain recording using a novel fully implantable pulse generator (Medtronic Activa PC+S), which has the capability of sensing and storing local field potentials (LFPs) recorded from implanted electrodes, in addition to providing therapeutic deep brain stimulation (DBS). 2) Study acute and chronic effects of therapeutic DBS on cortical LFPs. 3) Study feasibility of the use of brain signals as feedback either directly to the patient or for DBS stimulation adjustments.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1
• Est. completion date: July 31, 2020
• Est. primary completion date: July 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 45 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Diagnosis of idiopathic Parkinson's Disease (PD).

2. Age 45-75 years

3. UPDRS III motor score (off PD medications) = 25

4. Demonstrated good response (= 30%) to Sinemet or dopamine agonist medications as assessed by total UPDRS III score (off and on meds)

5. Approved for unilateral subthalamic nucleus (STN)- or globus pallidus internus (GPi)-DBS surgery to treat their clinical motor signs and plan to undergo the standard of care procedure within the next four months

6. Cleared to be scanned in a 7 tesla magnet

7. Written documentation of willingness to participate in the study per protocol as evidenced by the informed consent process

Exclusion Criteria:

1. Clinically significant medical disease that would increase the risk of developing pre- or post-operative complications (e.g., significant cardiac or pulmonary disease)

2. Evidence of secondary or atypical parkinsonism

3. Dementia as evidenced by impairment in two neuropsychological domains and impaired or borderline neuropsychological function in one additional domain.

4. Unable to undergo magnetic resonance imaging (e.g., due to incompatible implanted pacemaker)

5. Previous pallidotomy or DBS surgery

6. Women who are currently pregnant or are breast feeding

7. MRI showing cortical atrophy out of proportion to age and/or MRI showing focal brain lesions that could indicate a non-idiopathic movement disorder

8. Any prior intracranial surgery

9. Subjects with depression defined according to Diagnostic and Statistical Manual V criteria and a scored on a validated depression assessment scale

10. History of seizures

11. Immunocompromised

12. Requires diathermy, electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) to treat a chronic condition

13. Has an implanted electronic device such as a neurostimulator, cardiac pacemaker or medication pump.

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Device:
• Activa PC+S
DBS

Locations

Country	Name	City	State
United States	University of Minnesota	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cortical and sub-cortical brain signals using Activa PC+S	Establish whether it is possible to record a reliable cortical and subcortical brain signal using Activa PC+S.	12 months